The fight against Tuberculosis (TB) remains a critical global health challenge. Despite advancements in healthcare, early diagnosis remains a hurdle. This article aims to explore the contemporary diagnostic approaches available in healthcare today.
The conventional method for TB diagnosis is the sputum smear microscopy. It is cost-effective and provides rapid results. However, its sensitivity is limited, especially in HIV co-infected patients and children. The Culture method, although more sensitive, is time-consuming and requires sophisticated laboratories, limiting its use in resource-limited settings.
GeneXpert MTB/RIF, a real-time polymerase chain reaction (PCR) based test, has revolutionized TB diagnosis. It provides results within hours and has high sensitivity and specificity. It also detects rifampicin resistance, aiding in the management of drug-resistant TB. Nevertheless, its high cost and need for regular calibration make it less feasible for low-income countries.
Tuberculin skin test (TST) and Interferon Gamma Release Assays (IGRAs) are immunological tests used to detect latent TB infection. TST is inexpensive and easy to perform but has low specificity in BCG-vaccinated individuals. IGRAs, although more specific, are expensive and require a well-equipped laboratory.
Radiology plays a crucial role in TB diagnosis. Chest radiography can detect pulmonary TB, while CT and MRI are useful in diagnosing extrapulmonary TB. However, imaging cannot confirm TB and needs to be complemented by microbiological or histological confirmation.
In conclusion, while significant strides have been made in TB diagnosis, challenges persist. The ideal diagnostic tool should be sensitive, specific, rapid, affordable, and easy to use. Hence, there is a pressing need for continuous research and innovation to develop such a tool, especially for use in resource-limited settings.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation